Specifications {#s0005}
==============

Organism/cell line/tissue*Homo sapiens*Sex11 males 18 femalesSequencer or array typeGPL\#18159: Agilent-031181 Unrestricted Human miRNA version 16.0 MicroarrayData formatRaw and ProcessedExperimental factorsThree histological grades of Intrahepatic cholangiocarcinoma (ICC) tumor vs. distal non-tumor sections (from the ICC patient) vs. non-ICC "normal" liver biopsy FFPE.Experimental featuresmiRNA expression in FFPE samples of three histological grades of ICC tumor tissues when compared to both distal non-tumor samples (from the same ICC patients) and also non-endemic, non-ICC, "normal" liver biopsies.ConsentInstitutional Review Board reviewedSample source locationThailand; Washington D.C., United States

Direct link to deposited data

Deposited data can be found here: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53992>.

Experimental design, materials and methods {#s0010}
==========================================

Study samples {#s0015}
-------------

Intrahepatic cholangiocarcinoma (ICC) formalin-fixed, paraffin-embedded tissues (FFPE) were obtained from histologically confirmed *O. viverrini* (OV) induced ICC cases archived at the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University (KKU), Thailand ([Table 1](#t0005){ref-type="table"}). The histological subtypes of ICC cases were determined by Hematoxylin and Eosin (H & E) staining of tissue by pathologists at KKU (BS) and independently confirmed by a pathologist (SEE) at the George Washington University (GWU). The ICC FFPE blocks were then macrodissected into ICC tumor tissue (cholangiocarcinoma tumor tissue or CTT) and distal non-tumor (D-NT) tissue (i.e. tissue distal from dysplasia or frank carcinoma). In addition, 13 non-tumor FFPE blocks ([Table 2](#t0010){ref-type="table"}) derived from liver biopsies of individuals suspected of severe steatosis or steatohepatitis prior to gastric bypass surgery were included as normal non-tumor tissue (N-NT) to assess baseline liver histology of individuals with no ICC and do not reside in an OV endemic region. Details of the specimens, including histological confirmation and preparation of FFPE samples, can be found in [@bb0005].

The Institutional Review Boards from both KKU and GWU determined that the samples did not meet the definition of human subjects research, i.e., a living individual about whom an investigator conducting research obtains: a) data through intervention or interaction with the individual or b) private identifiable information. This determination was made since the samples were limited to pre-existing, de-identified specimen analysis labeled with a random code.

RNA isolation {#s0020}
-------------

Total RNA was extracted from each of the FFPE blocks using the miRNeasy FFPE kit (Qiagen) following the manufacturer\'s protocol [@bb0010] and also further detailed in [@bb0005]. RNA quality and integrity were examined by spectrophotometry (Nano Drop 2000, Thermo Scientific) and by using an Agilent 2100 Bioanalyzer (RNA 6000 Nano and Small RNA Kits, Agilent). The 260/280 ratios obtained were approximately 2.0, indicating that the RNA was pure. The purified RNA exhibited 260/230 ratios greater than 1.9, or only slightly less than the range of 2.0--2.2 expected, indicating no significant contaminants.

Analysis by the Agilent Bioanalyzer produced RNA integrity numbers (or RIN scores) of two to three, with 28S and 18S peaks largely absent. This value was below the quality criteria (RIN greater than or equal to eight) and indicated degraded RNA. RNA obtained from FFPE tissue samples often has slight modifications and degradation due to the process of formalin fixation and duration of storage is expected [@bb0015], [@bb0020]. However, due to the stable nature of miRNAs in the FFPE matrix, as shown by us [@bb0005], [@bb0010] as well as others [@bb0025], [@bb0030], the extracted RNA was determined to be suitable for subsequent analysis of miRNA profiles by microarray.

Microarray analysis {#s0025}
-------------------

Purified RNA from all 46 cases samples including 16 CTT and both types of controls (15, D-NT and 13, N-NT) ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}) were profiled on the Agilent human miRNA microarray (miRBase Release 16.0). Hybridization and further details are available in the Gene Expression Omnibus (GEO) database and also found in [@bb0005].

Data normalization and analysis {#s0030}
-------------------------------

The feature intensity of each sample was transferred to digital data and then log~2~ transformed using Agilent Feature Extraction (V.10.7). All the raw data files in text (.txt) format were analyzed (including statistical analysis) with Agilent GeneSpring software (GX 12.6) (<http://genespring-support.com/files/gs_12_6/GeneSpring-manual.pdf>) [@bb0035].

To determine the presence of aberrantly expressed miRNAs, a new "*project*" and new "*experiment*" were created within GeneSpring (GX 12.6), with *miRNA* selected for analysis type and the data import wizard used for the workflow type. After uploading the raw intensity files into *GeneSpring*, *31181_v18_0 technology* was selected ([Table 3](#t0015){ref-type="table"}). The threshold raw signals were set to 1.0 and 90 percentile and "*shift normalization*" was performed to standardize the statistical parameters across all samples ([Table 3](#t0015){ref-type="table"}). No baseline transformation was performed.

Four different methods were used to analyze this sample set as shown in [Fig. 1](#f0005){ref-type="fig"} and in [Table 3](#t0015){ref-type="table"}. Dysregulated miRNAs were reported as associated with either ICC itself or with ICC stratified by histological subtype as reported in [@bb0005].•*Analysis One*: Normal, non-tumor tissues (N-NT), distal normal tissues (D-NT), and ICC tumor tissues (CCT) samples were analyzed with 3D Principal Components Analysis (PCA), Hierarchical Clustering, and One-way analysis of variance (ANOVA).•*Analysis Two*: Paired Student\'s t-test was used to analyze CTT versus D-NT stratified by the histological subtype of ICC.•*Analysis Three*: Unpaired Student\'s t-test was used to analyze each histological subtype of ICC tumor (including CTT, D-NT and when available necrotic tissue) versus N-NT, (non-ICC normal, non-tumor tissue).•*Analysis Four*: One-way ANOVA was used to analyze the differences among the three histological subtypes of ICC FFPE samples (including CTT, necrotic tissue and D-NT).

In all analyses below, subsequent "*interpretations*" were created in GeneSpring (GX 12.6) with the conditions selected, including "*non-averaged*" selected over replicates, and the measurements flagged as "*default*." In most analyses, unless otherwise noted, the probe sets were filtered by expression value (i.e. 30--336133.0) with at least 50% of the values greater than 30 in any one condition within range.*Analysis One: CTT versus N-NT versus D-NT by one-way ANOVA*1)*In this first experimental design (*[Table 3](#t0015){ref-type="table"}*), the FFPE samples were grouped accordingly: 13 N-NT, 15 D-NT, 2 necrotic samples, and 16 CCT samples (without consideration of histological subtype).*2)*For "Quality Control", the correlation coefficient (CC) and 3D Principal Component Analysis (PCA) scores were used to determine associations among the samples. The CC of sample Y62-N1 (D-NT from a papillary ICC block) was below an acceptable CC (\< 0.7) and the sample removed from subsequent analyses. Principle Components Analysis demonstrated that N-NT samples clustered together, and were distinct from the other types of samples (CTT and D-NT). Further details regarding principal component analysis can be found below:*•*Algorithm: Principal Components Analysis*•*Parameters:*○*Column indices: \[1--45\]*○*Pruning option: \[numPrincipalComponents,* [@bb0020]*\]*○*Mean centered: True*○*Scale: True*○*3-D scores: True*○*PCA on: Columns*3)*Hierarchical Clustering analysis of the samples\' correlations was then conducted on both "entities" and "conditions" on the normalized intensity values after filtering by Euclidean distance metric and Median linkage rule. Hierarchical Clustering details are summarized below:*•*Clustering Algorithm: Hierarchical*•*Clustered By: Normalized intensity values*•*Clustered On: Entities and Conditions*•*Similarity Measure: Euclidean*•*Linkage Rule: Median*•*Cluster Within Conditions: No*4)*To analyze the differences between CTT versus D-NT versus N-NT, a one-way ANOVA was conducted (with no post hoc pairwise testing) with asymptotic p-value computation without correction completed. Fold changes (≥ 2.0) were analyzed under pairs of conditions with two minimum numbers of pairs. Fewer differences were observed between tumor tissue (CTT) and distal non-tumor tissue (D-NT) than between D-NT and N-NT, confirming the PCA and Hierarchical Clustering results.Analysis Two: CTT versus D-NT by paired Student\'s t-test*1)CTT samples were again grouped by histological subtype and compared to adjacent non-tumor tissue (D-NT) (see [Table 1](#t0005){ref-type="table"}): i.e., moderately differentiated CTT versus D-NT from the same block, well-differentiated CTT versus D-NT from the same block, and papillary CTT versus D-NT from the same block ([Table 3](#t0015){ref-type="table"}, Box 2 [Fig. 1](#f0005){ref-type="fig"}).2)To filter probe sets by expression value, in each case the "*entity*" and "*interpretation*" were selected and filtered by raw data values. The lower cut-off value was set to 30 and at least 50% of the values in any one condition within range for well-differentiated CTT versus its D-NT and papillary CTT versus its D-NT. In the case of moderately differentiated CTT versus necrosis versus N-NT, at least 50% of the values in one condition were greater than 20.3)In the "*analysis workflow*" in GeneSpring (GX 12.6), paired Student\'s t-test (*p* \< 0.05) was performed to analyze differences among CTT versus D-NT samples of well-differentiated ICC and papillary ICC by asymptotic *p*-value computation without correction for multiple testing. Further a fold change cut-off of 2.0 between conditions (CTT against D-NT) was performed. Only fold changes ≥ 4.0 were analyzed for moderately differentiated CTT versus moderately differentiated necrosis versus moderately differentiated D-NT but statistical significance was not calculated from this limited sample set consisting of only two moderately differentiated CTT samples and a single D-NT sample.4)A Venn diagram was plotted to determine the shared dysregulated miRNAs among the groups of analyzed after filtering, statistical analysis, and fold change selection (data not shown).*Analysis Three: ICC (CTT + D-NT) versus N-NT by unpaired Student\'s t-test*1)All CTT, necrotic, and D-NT samples were grouped (and referred to as "tumor" or "ICC" as a whole) according to histological subtype to generate four different groups of samples: (1) N-NT, (2) well-differentiated ICC, (3) papillary ICC and (4) moderately differentiated ICC ([Table 3](#t0015){ref-type="table"}, Box 3 [Fig. 1](#f0005){ref-type="fig"}).2)When conducting unpaired Student\'s t-test (with Benjamini Hochberg False Discovery Rate correction undertaken due to multiple testing), each comparison was given its own *p*-value cut, when testing the three histological subtypes of ICC versus normal liver tissue (N-NT) by asymptotic *p*-value computation: *p* \< 0.01 was set for well-differentiated ICC versus N-NT and *p* \< 0.005 for papillary and moderately differentiated ICC versus N-NT (*p*-values after Benjamini Hochberg False discovery rate correction). A fold change cut-off of 2.0 between conditions (ICC versus N-NT) was also performed.3)A Venn diagram was plotted to show the shared dysregulated miRNAs after filtering, statistical analysis and fold change selection (Center Box, [Fig. 1](#f0005){ref-type="fig"}).*Analysis Four: Histological subtype analysis of ICC by one-way ANOVA*1)Here the subtypes of ICC (CTT, necrotic, and D-NT samples were grouped and referred to as "tumor" or "ICC" as a whole) were analyzed against each other ([Table 3](#t0015){ref-type="table"}, Box 4 [Fig. 1](#f0005){ref-type="fig"}).2)Fold change selection was performed by selecting a cut-off of 2.0 in two pairs of conditions. Further a one-way ANOVA (no pairwise poc hoc testing) with Benjamini Hochberg False Discovery Rate correction was performed among the pairs of conditions by asymptotic *p*-value computation and *p* \< 0.05 (*p*-values after Benjamini Hochberg False discovery rate correction).3)Significantly dysregulated miRNAs, as determined in Analysis Four, were plotted by Venn diagram and compared to the dysregulated miRNAs determined by Analysis Three for observation of overlap (Center Box, [Fig. 1](#f0005){ref-type="fig"}).
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![Flow diagram of analyses and associated miRNAs found to be dysregulated. A final qPCR verification step was also completed to confirm the magnitude and expression levels determined by microarray but not described herein [@bb0005]. A Venn diagram [@bb0045] highlights overlapping miRNAs identified in analysis three and analysis four, yielding seven overlapping miRNAs. Abbreviations are as follows: Intrahepatic cholangiocarcinoma tumor tissue (CTT); distal non-tumor tissue (D-NT); and normal non-tumor tissue (N-NT).](gr1){#f0005}

###### 

Intrahepatic cholangiocarcinoma (ICC) FFPE cases utilized in the study denoted with associated raw data files and accession numbers. Distal tumor (D-NT) and tumor (CTT) samples types are indicated for each case.

  NCBI accession number   Title      Sample type     Sex                                                                   Age   Tumor histological grade    Gross Classification                                      Raw intensity files
  ----------------------- ---------- --------------- --------------------------------------------------------------------- ----- --------------------------- --------------------------------------------------------- ---------------------------------------------------------------------
  GSM1305122              B70-N1     Distal normal   Male                                                                  61    Well differentiated         Mass-forming                                              GSM1305122_US12302349_253118113117_S01_miRNA_1100_Jul11_1\_3.txt.gz
  GSM1305123              B70-T1     Tumor           GSM1305123_US12302349_253118113117_S01_miRNA_1100_Jul11_1\_4.txt.gz                                                                                               
  GSM1305124              B79-N1     Distal normal   Male                                                                  61    Well differentiated         Periductal infiltrating, invasive intraductal and mixed   GSM1305124_US12302349_253118113117_S01_miRNA_1100_Jul11_2\_1.txt.gz
  GSM1305125              B79-T1     Tumor           GSM1305125_US12302349_253118113117_S01_miRNA_1100_Jul11_2\_2.txt.gz                                                                                               
  GSM1305126              B83-N1     Distal normal   Female                                                                53    Well differentiated         Mass-forming                                              GSM1305126_US12302349_253118113117_S01_miRNA_1100_Jul11_2\_3.txt.gz
  GSM1305127              B83-T1     Tumor           GSM1305127_US12302349_253118113117_S01_miRNA_1100_Jul11_2\_4.txt.gz                                                                                               
  GSM1305108              B99-N1     Distal normal   Male                                                                  48    Well differentiated         Mass-forming                                              GSM1305108_US12302349_253118112956_S01_miRNA_1100_Jul11_2\_1.txt.gz
  GSM1305109              B99-T1     Tumor           GSM1305109_US12302349_253118112956_S01_miRNA_1100_Jul11_2\_2.txt.gz                                                                                               
  GSM1305110              Y42-N1     Distal normal   Male                                                                  61    Well differentiated         Mass-forming                                              GSM1305110_US12302349_253118112956_S01_miRNA_1100_Jul11_2\_3.txt.gz
  GSM1305111              Y42-T1     Tumor           GSM1305111_US12302349_253118112956_S01_miRNA_1100_Jul11_2\_4.txt.gz                                                                                               
  GSM1305106              B90-N1     Distal normal   Male                                                                  58    Well differentiated         Mass-forming                                              GSM1305106_US12302349_253118112956_S01_miRNA_1100_Jul11_1\_3.txt.gz
  GSM1305107              B90-T1     Tumor           GSM1305107_US12302349_253118112956_S01_miRNA_1100_Jul11_1\_4.txt.gz                                                                                               
  GSM1305100              B91-Nec1   Necrotic        Male                                                                  63    Moderately differentiated   Mass forming                                              GSM1125485_US12302349_253118112871_S01_miRNA_107_Sep09_2\_1.txt.gz
  GSM1305101              B91-T1     Tumor           GSM1125486_US12302349_253118112871_S01_miRNA_107_Sep09_2\_2.txt.gz                                                                                                
  GSM1305102              Y70-N1     Distal normal   Female                                                                63    Moderately differentiated   Mass forming                                              GSM1125487_US12302349_253118112871_S01_miRNA_107_Sep09_2\_3.txt.gz
  GSM1305103              Y70-T1     Tumor           GSM1125488_US12302349_253118112871_S01_miRNA_107_Sep09_2\_4.txt.gz                                                                                                
  GSM1305116              Y56-N1     Distal normal   Female                                                                56    Papillary carcinoma         Periductal infiltrating, invasive intraductal and mixed   GSM1305116_US12302349_253118112957_S01_miRNA_1100_Jul11_2\_1.txt.gz
  GSM1305117              Y56-T1     Tumor           GSM1305117_US12302349_253118112957_S01_miRNA_1100_Jul11_2\_2.txt.gz                                                                                               
  GSM1305118              Y62-N1     Distal normal   Male                                                                  57    Papillary carcinoma         Periductal infiltrating, invasive intraductal and mixed   GSM1305118_US12302349_253118112957_S01_miRNA_1100_Jul11_2\_3.txt.gz
  GSM1305119              Y62-T1     Tumor           GSM1305119_US12302349_253118112957_S01_miRNA_1100_Jul11_2\_4.txt.gz                                                                                               
  GSM1305114              B40-N1     Distal normal   Male                                                                  64    Papillary carcinoma         Mass forming                                              GSM1305114_US12302349_253118112957_S01_miRNA_1100_Jul11_1\_3.txt.gz
  GSM1305115              B40-T1     Tumor           GSM1305115_US12302349_253118112957_S01_miRNA_1100_Jul11_1\_4.txt.gz                                                                                               
  GSM1305129              Y83-N1     Distal normal   Female                                                                51    Papillary carcinoma         Mass forming                                              GSM1305129_US12302349_253118113118_S01_miRNA_1100_Jul11_1\_2.txt.gz
  GSM1305130              Y83-T1     Tumor           GSM1305130_US12302349_253118113118_S01_miRNA_1100_Jul11_1\_3.txt.gz                                                                                               
  GSM1305131              Y88-N2     Distal normal   Female                                                                58    Papillary carcinoma         Periductal infiltrating, invasive intraductal and mixed   GSM1305131_US12302349_253118113118_S01_miRNA_1100_Jul11_1\_4.txt.gz
  GSM1305132              Y88-T1     Tumor           GSM1305132_US12302349_253118113118_S01_miRNA_1100_Jul11_2\_1.txt.gz                                                                                               
  GSM1305133              Y89-N      Distal normal   Female                                                                60    Papillary carcinoma         Mass forming                                              GSM1305133_US12302349_253118113118_S01_miRNA_1100_Jul11_2\_2.txt.gz
  GSM1305134              Y89-Nerc   Necrotic        GSM1305134_US12302349_253118113118_S01_miRNA_1100_Jul11_2\_3.txt.gz                                                                                               
  GSM1305135              Y89-T      Tumor           GSM1305135_US12302349_253118113118_S01_miRNA_1100_Jul11_2\_4.txt.gz                                                                                               
  GSM1305138              Y93-N1     Distal normal   Male                                                                  63    Papillary carcinoma         Periductal infiltrating, invasive intraductal and mixed   GSM1305138_US12302349_253118113119_S01_miRNA_1100_Jul11_1\_3.txt.gz
  GSM1305139              Y93-T1     Tumor           GSM1305139_US12302349_253118113119_S01_miRNA_1100_Jul11_1\_4.txt.gz                                                                                               
  GSM1305140              Y96-N1     Distal normal   Female                                                                64    Papillary carcinoma         Mass forming                                              GSM1305140_US12302349_253118113119_S01_miRNA_1100_Jul11_2\_1.txt.gz
  GSM1305141              Y96-T1     Tumor           GSM1305141_US12302349_253118113119_S01_miRNA_1100_Jul11_2\_2.txt.gz                                                                                               

###### 

Additional FFPE cases, normal non-tumor tissue (N-NT) from non-ICC gastric bypass patients, utilized in the study denoted with raw data file names and accession numbers.

  NCBI accession number   Title   Sample Type     Raw intensity files
  ----------------------- ------- --------------- ---------------------------------------------------------------------
  GSM1305096              3325A   Non-ICC, N-NT   GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1\_1.txt.gz
  GSM1305097              3337A   Non-ICC, N-NT   GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1\_2.txt.gz
  GSM1305098              3356A   Non-ICC, N-NT   GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1\_3.txt.gz
  GSM1305099              3377A   Non-ICC, N-NT   GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1\_4.txt.gz
  GSM1305104              3575A   Non-ICC, N-NT   GSM1305104_US12302349_253118112956_S01_miRNA_1100_Jul11_1\_1.txt.gz
  GSM1305105              3578A   Non-ICC, N-NT   GSM1305105_US12302349_253118112956_S01_miRNA_1100_Jul11_1\_2.txt.gz
  GSM1305112              3641A   Non-ICC, N-NT   GSM1305112_US12302349_253118112957_S01_miRNA_1100_Jul11_1\_1.txt.gz
  GSM1305113              3707A   Non-ICC, N-NT   GSM1305113_US12302349_253118112957_S01_miRNA_1100_Jul11_1\_2.txt.gz
  GSM1305120              3563A   Non-ICC, N-NT   GSM1305120_US12302349_253118113117_S01_miRNA_1100_Jul11_1\_1.txt.gz
  GSM1305121              3564A   Non-ICC, N-NT   GSM1305121_US12302349_253118113117_S01_miRNA_1100_Jul11_1\_2.txt.gz
  GSM1305128              3869A   Non-ICC, N-NT   GSM1305128_US12302349_253118113118_S01_miRNA_1100_Jul11_1\_1.txt.gz
  GSM1305136              3967A   Non-ICC, N-NT   GSM1305136_US12302349_253118113119_S01_miRNA_1100_Jul11_1\_1.txt.gz
  GSM1305137              4565A   Non-ICC, N-NT   GSM1305137_US12302349_253118113119_S01_miRNA_1100_Jul11_1\_2.txt.gz

###### 

Key parameters utilized in four independent analyses.

  1.0 threshold to raw signals, 90 percentile shift normalization to all samples, 31181_v18_0 technology                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------- ---------------------------------- ---------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------
  N-NT vs. CTT vs. D-NT vs. necrosis                                                                       CTT vs. D-NT                       ICC (CTT + D-NT) vs. N-NT    Well differentiated vs. papillary vs. moderately differentiated                                                                                                                                                                                                             
                                                                                                           Well differentiated CTT vs. D-NT   Papillary CTT vs. D-NT       Moderately CTT vs. Nec vs. D-NT                                   Well differentiated (CTT + D-NT) vs. N-NT                           Papillary (CTT + D-NT + Nec) vs. N-NT                              Moderately differentiated (CTT + D-NT + Nec) vs. N-NT              Well differentiated (CTT + D-NT) vs. Papillary (CTT + D-NT + Nec) vs. Moderately differentiated (CTT + D-NT + Nec)
  3D PDA                                                                                                   Raw value \> 30                    Raw value \> 20              Raw value \> 30                                                   Raw value \> 30                                                                                                                                                                                           
  Raw \> 30                                                                                                Paired t-test, *p* \< 0.05         Paired t-test, *p* \< 0.05   N/A                                                               unpaired t-test, Benjamini Hochberg FDR correction, *p* \< 0.01     unpaired t-test, Benjamini Hochberg FDR correction, *p* \< 0.005   unpaired t-test, Benjamini Hochberg FDR correction, *p* \< 0.005   Fold change (FC) \> 2 in 2 pairs
  Hierarchical clustering,                                                                                 FC \> 2                            FC \> 4 in 2 pairs           FC \> 2                                                           One-way ANOVA, Benjamini Hochberg FDR correction, p(corr) \< 0.05                                                                                                                                         
  Euclidean distance metric, Median linkage rule                                                                                                                                                                                                                                                                                                                                                                                                       
  One-way ANOVA, *p* \< 0.05                                                                                                                                                                                                                                                                                                                                                                                                                           

Abbreviations are as follows: Intrahepatic cholangiocarcinoma tumor tissue (CTT); distal non-tumor tissue (D-NT); and normal non-tumor tissue (N-NT).
